Canntab Sets New All-Time High Trading Prices and Volume

- September 20th, 2018

Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company’s common shares (“Common Shares”) yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the “CSE”).

Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company’s common shares (“Common Shares”) yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the “CSE”). These numbers exceed the Company’s previous all-time highs by 39.2% and 15.6%, which were also set earlier this week. In addition, the Company traded an aggregate of 1,583,326 Common Shares yesterday at a total dollar value of $2.06M, which constitutes its all-time high daily volume and exceeds the Company’s previous highs, set on the Company’s opening day of trading on April 20, 2018.

“We are thrilled that the investment community is taking notice of the positive developments occurring at Canntab. Our team has been focusing its efforts on developing the core business, and our dedication is being rewarded in the market. As always, we would like to thank our shareholders, both new and longstanding, for their support,” said Jeff Renwick, CEO and a director of Canntab.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Richard Goldstein, CFO
Office: 416 957-6303

Email: info@canntab.ca

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation. 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *